Genomic variation-guided management in chronic hepatitis C.

Abstract

In 2009, several different research groups simultaneously identified the polymorphisms close to IL28B gene as an important predictor of therapeutic response for chronic hepatitis C (CHC) patients receiving interferon-based treatment using approaches of genome-wide association studies. They also found that these genetic variations were strongly associated with the spontaneous viral clearance of hepatitis C virus (HCV) infection. Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. All these lines of evidence usher in a new genomic era for the management of HCV infection. In this article, advances in recent genome-wide association studies regarding HCV infection, and their impacts on the management of CHC patients will be reviewed. In addition, the clinical usefulness of genomic variations on the addition of direct antiviral agents to current standard of care will be discussed.

• Authors: Ching-Sheng Hsu, Jia-Horng Kao
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 6 Issue 4 Pg. 497-506 (Aug 2012) ISSN: 1747-4132 [Electronic] England
• PMID: 22928901 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiviral Agents
• IFNL3 protein, human
• Interferon-alpha
• Interleukins
• Recombinant Proteins
• Polyethylene Glycols
• Ribavirin
• Interferons
• Pyrophosphatases
• ITPA protein, human
• peginterferon alfa-2a

Topics

• Antiviral Agents (therapeutic use)
• Genome-Wide Association Study
• Genotype
• Hepatitis C, Chronic (drug therapy, genetics, virology)
• Humans
• Interferon-alpha (therapeutic use)
• Interferons
• Interleukins (genetics)
• Pharmacogenetics
• Polyethylene Glycols (therapeutic use)
• Precision Medicine
• Pyrophosphatases (genetics)
• Recombinant Proteins (therapeutic use)
• Ribavirin (therapeutic use)